Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.
Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.
Van de Veire
Sara
S
Vesalius Research Center, KU Leuven, Leuven B-3000, Belgium.
Stalmans
Ingeborg
I
Heindryckx
Femke
F
Oura
Hajimu
H
Tijeras-Raballand
Annemilaï
A
Schmidt
Thomas
T
Loges
Sonja
S
Albrecht
Imke
I
Jonckx
Bart
B
Vinckier
Stefan
S
Van Steenkiste
Christophe
C
Tugues
Sònia
S
Rolny
Charlotte
C
De Mol
Maria
M
Dettori
Daniela
D
Hainaud
Patricia
P
Coenegrachts
Lieve
L
Contreres
Jean-Olivier
JO
Van Bergen
Tine
T
Cuervo
Henar
H
Xiao
Wei-Hong
WH
Le Henaff
Carole
C
Buysschaert
Ian
I
Kharabi Masouleh
Behzad
B
Geerts
Anja
A
Schomber
Tibor
T
Bonnin
Philippe
P
Lambert
Vincent
V
Haustraete
Jurgen
J
Zacchigna
Serena
S
Rakic
Jean-Marie
JM
Jiménez
Wladimiro
W
Noël
Agnes
A
Giacca
Mauro
M
Colle
Isabelle
I
Foidart
Jean-Michel
JM
Tobelem
Gerard
G
Morales-Ruiz
Manuel
M
Vilar
José
J
Maxwell
Patrick
P
Vinores
Stanley A
SA
Carmeliet
Geert
G
Dewerchin
Mieke
M
Claesson-Welsh
Lena
L
Dupuy
Evelyne
E
Van Vlierberghe
Hans
H
Christofori
Gerhard
G
Mazzone
Massimiliano
M
Detmar
Michael
M
Collen
Désiré
D
Carmeliet
Peter
P
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000517:prevention & control; D002829:Choroid / Q000098:blood supply; D004195:Disease Models, Animal; D005128:Eye Diseases / Q000473:pathology; D006801:Humans; D008114:Liver Neoplasms, Experimental / Q000098:blood supply / Q000517:prevention & control; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010212:Papilloma / Q000098:blood supply / Q000139:chemically induced / Q000517:prevention & control; D000072483:Placenta Growth Factor; D011257:Pregnancy Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D012878:Skin Neoplasms / Q000098:blood supply / Q000139:chemically induced / Q000517:prevention & control
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; C000608036:PGF protein, human; C000608037:Pgf protein, mouse; D011257:Pregnancy Proteins; D000072483:Placenta Growth Factor